The estimated Net Worth of Jeffrey Paley is at least $477 ezer dollars as of 3 December 2018. Jeffrey Paley owns over 15,000 units of Avenue Therapeutics Inc stock worth over $231,023 and over the last 11 years Jeffrey sold ATXI stock worth over $245,600.
Jeffrey has made over 2 trades of the Avenue Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Jeffrey bought 15,000 units of ATXI stock worth $78,600 on 3 December 2018.
The largest trade Jeffrey's ever made was selling 20,000 units of Avenue Therapeutics Inc stock on 14 August 2014 worth over $245,600. On average, Jeffrey trades about 5,000 units every 225 days since 2013. As of 3 December 2018 Jeffrey still owns at least 79,663 units of Avenue Therapeutics Inc stock.
You can see the complete history of Jeffrey Paley stock trades at the bottom of the page.
Jeffrey's mailing address filed with the SEC is 2 Gansevoort St 9TH FLOOR, New York, NY 10014, USA.
Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss és Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Avenue Therapeutics Inc executives and other stock owners filed with the SEC include: